Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The effect of Pulmonary Rehabilitation in patients with bronchiectasis (BC) is not sufficiently studied. The aim of this study is to assess the clinical and biological response of a Pulmonary Rehabilitation Program (PRP) for 12 weeks in BC vs PRP plus hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB).

Methods: single center randomized controlled trial, parallel treatment design: Participants will be randomized assigned either will receive (n=14) PRP for 60 minutes, two supervised sessions per week in the hospital and one unsupervised session at home vs PRP (n=14) plus ONS (one can per day).

Outcome assessments will be performed at baseline, 12 weeks and 24 weeks:

1.- effort capacity \–cardiopulmonary exercise test-, 2.- body composition (anthropometry, lean body mass by dual energy X-ray absorptiometry and bioimpedance, phase angle), 3.- peripheral muscle strength (dynamometry and respiratory -PEM (maximum expiratory pressure)and PIM (minimum expiratory pressure)-), 4.- spirometry, 5.- respiratory symptoms (bronchorrhea, dyspnoea, exacerbations),6.- level of physical activity (IPAQ questionnaire plus objective physical activity (WGT3X)), 7.- quality of life (QOL-B-Spain) , 8.-psychological symptoms (HASD) and 9.- biological markers of inflammation (leptin, adiponectin, interleukin-6, tumor necrosis factor-alpha, ultrasensitive C-reactive protein, GPR55 (G protein-coupled receptor 55) RNAm (messenger ribonucleic acid) expression in white blood cells) and oxidation (total antioxidant capacity, superoxide dismutase activity, 8-iso-prostaglandin F2a, Thiobarbituric acid reactive substances).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pulmonary Rehabilitation in Non-Cystic Fibrosis Bronchiectasis

NCT02823587

Bronchiectasis

UNKNOWN NA

Short-and Long-term Effects of a Home-based Rehabilitation Program in Patients With Bronchiectasis

NCT02731482

Bronchiectasis

COMPLETED NA

The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis

NCT02883101

Non-cystic Fibrosis Bronchiectasis

COMPLETED NA

Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis

NCT00868075

Bronchiectasis

COMPLETED PHASE4

Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program

NCT05369624

Non-cystic Fibrosis Bronchiectasis Pulmonary Rehabilitation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchiectasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary Rehabilitation (PRP)

Group Type OTHER

Pulmonary Rehabilitation

Intervention Type OTHER

Pulmonary Rehabilitation plus oral nutritional supplement

Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)

Group Type OTHER

Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pulmonary Rehabilitation

Intervention Type OTHER

Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ages from 18-80 (both included)
* Patients with bronchiectasis, not cystic fibrosis bronchiectasis.
* Bronchiectasis diagnosed by high resolution computed tomography (HRCT). of the chest
* Patients followed in Bronchiectasis and Cystic Fibrosis Units in the Hospital.
* BMI \> 18.5 in patients under 65 years old, and \> 20kg/m2 in patients over this age.
* Ambulatory patients.

Exclusion Criteria

* Use of oral corticoids.
* Respiratory exacerbation. If a patient had a respiratory exacerbation or a recent hospital admission, their participation will be postponed for at least 60 days til any acute disease is resolved.
* Prior oral or parenteral supplements intake.
* Traumatological, neurological or cardiovascular diseases that prevent patients from performing the training.
* Life threatening hemoptysis in the past year.
* Patients with cancer, major surgery in the previous three months, participating in another study, patients who are pregnant or may become pregnant, patients with acute intestinal disease, acute heart failure, severe hepatic failure or dialysis.
* Gastrectomy, gastroparesis or other alterations of gastric emptying.
* Enteral tube feeding, galactosemia, Fructosemia.
* Allergy or known sensitivity to any ingredient of the enteral formula.
* Cystic fibrosis.
* Included in active list for transplantation.
* Drug or alcohol abuse.
* No informed consent signed.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No